NCT07023861View on ClinicalTrials.gov

The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies

EARLY_PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 7, 2026

Study Completion Date

December 1, 2026

Conditions
Breast CancerGastric Cancer (GC)Urothelial Carcinoma (UC)
Interventions
DRUG

18F-FDG

18F-FDG is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15 mCi/kg.

DRUG

89Zr-LNCab190

89Zr-LNCab190 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi

DRUG

89Zr-LNCab002

89Zr-LNCab002 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi

DRUG

89Zr-LNCab072

89Zr-LNCab072 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi

Trial Locations (1)

214000

Affiliated Hospital of Jiangnan University, Wuxi

All Listed Sponsors
lead

Affiliated Hospital of Jiangnan University

OTHER